Terminated PHASE1 INTERVENTIONAL 1-arm NCT00515788

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

Phase I Study of Temozolomide and Intrathecal DepoCyt in Patients With Neoplastic Meningitis

Sponsor: Enzon Pharmaceuticals, Inc.

Updated 5 times since 2017 Last updated: Mar 8, 2012 Started: Feb 28, 2006 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated due to slow accrual with no expansion to additional phase.

Other terminated trials from Enzon Pharmaceuticals, Inc.

More terminations from Enzon Pharmaceuticals, Inc.

Other Neoplastic Meningitis trials with similar outcome

NCT00964743 · Phase NA · Feb 2011

Browse all Neoplastic Meningitis trials

A PHASE1 clinical study on Neoplastic Meningitis, this trial is terminated or withdrawn. The trial is conducted by Enzon Pharmaceuticals, Inc. and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Enzon Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
Schering-Plough

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States